Consolidated Statements of Operations - USD ($)	3 Months Ended	9 Months Ended
Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues	$ 5,888,450	$ 4,117,783	$ 14,927,691	$ 12,662,290
Cost of revenues	4,808,679	4,012,369	13,976,087	11,515,168
Research and development	6,315,613	8,469,623	20,719,989	19,024,728
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0	0	9,400,000	0
Selling, general, and administrative	5,147,166	7,894,291	24,971,438	24,310,324
Total operating costs and expenses	16,271,458	20,376,283	69,067,514	54,850,220
Operating loss	(10,383,008)	(16,258,500)	(54,139,823)	(42,187,930)
Other (expense) income:
Other (expense) income, net	(410,233)	(687,280)	4,398,585	(1,062,568)
Interest expense	(552,983)	(183,477)	(1,651,222)	(383,539)
Nonoperating Income (Expense), Total	(963,216)	(870,757)	2,747,363	(1,446,107)
Loss before provision (benefit) for income taxes and noncontrolling interests	(11,346,224)	(17,129,257)	(51,392,460)	(43,634,037)
Provision (benefit) for income taxes	46,633	47,387	(3,610,097)	142,183
Net loss	(11,392,857)	(17,176,644)	(47,782,363)	(43,776,220)
Less - loss attributable to noncontrolling interests	(16,907)	(202,375)	(93,257)	(514,877)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (11,375,950)	$ (16,974,269)	$ (47,689,106)	$ (43,261,343)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.21)	$ (0.48)	$ (1.04)	$ (1.37)
Weighted average common shares outstanding	55,239,119	35,053,218	45,867,567	31,663,221

The aggregate cost of goods produced and sold and services rendered during the reporting period.

Name:	us-gaap_CostOfRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.